Metabolomics study of treatment response to conbercept of patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy

Yinchen Shen, Hanying Wang, Xiaoyin Xu, Chong Chen, Shaopin Zhu, Lu Cheng, Junwei Fang, Kun Liu, Xun XuFrontiers in Pharmacology 2022 · DOI

TL;DR

This study uses metabolomics to identify serum biomarkers that predict treatment response to conbercept, an anti-VEGF drug, in patients with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV). They found that specific lipid metabolites, particularly lysophosphatidylcholine (LPC) 18:0, can distinguish between responders and non-responders, offering a potential tool for personalized treatment strategies.

What Problem Does This Paper Address?

Neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) are leading causes of vision loss in older adults. While anti-vascular endothelial growth factor (anti-VEGF) therapies like conbercept are effective, a significant portion of patients (around 30%) do not respond well. Currently, there's a lack of reliable methods to predict which patients will benefit from these treatments, leading to potentially ineffective therapies and delayed interventions. This paper aims to bridge this gap by investigating whether differences in the body's metabolic profile (metabolome) can predict treatment response to conbercept.

Methods

The researchers conducted a prospective, longitudinal study across 13 clinical sites in China. They enrolled patients with nAMD or PCV who received intravitreal injections of conbercept. Patients were categorized into "responders" and "non-responders" based on changes in their retinal fluid and thickness after treatment. Serum samples were collected from both groups and analyzed using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) to identify and quantify metabolites.

Statistical analysis involved:

  • Principal Component Analysis (PCA) and Partial Least Squares Discriminant Analysis (PLS-DA): These multivariate statistical techniques were used to visualize and identify differences in the overall metabolic profiles between responders and non-responders.
  • Area Under the Curve (AUC): Calculated from Receiver Operating Characteristic (ROC) curves to screen for potential biomarkers that can effectively discriminate between the two groups.
  • MetaboAnalyst 5.0: Used for identifying metabolite subclasses and enriched metabolic pathways.
  • Lipid Genie's Lipid Viewer: Employed to explore potential genetic variants associated with identified metabolites.

Datasets

The study utilized serum samples from two groups of patients:

  • Discovery Group: 132 patients from Shanghai General Hospital.
  • Validation Group: 87 patients from 12 other clinical sites in China.

These datasets were used to identify potential biomarkers in the discovery group and then validate their predictive accuracy in the independent validation group.

Key Insights and Ideas

  • Metabolic Fingerprints of Response: The study's core insight is that distinct metabolic profiles exist before treatment, differentiating patients who will respond to conbercept from those who won't. This suggests that treatment response is not solely determined by the drug's action but also by the patient's underlying metabolic state.
  • Lipids as Key Players: The most significant metabolic differences were observed in lipid metabolism, particularly in lysophosphatidylcholine (LPC) and diacylglycerophosphocholine pathways. This highlights the crucial role of lipids in the pathogenesis and response to treatment for these eye conditions.
  • LPC 18:0 as a Promising Biomarker: The specific lipid LPC 18:0 emerged as a strong candidate biomarker, demonstrating high accuracy in distinguishing responders from non-responders. This finding is particularly exciting as it offers a tangible tool for clinical application.
  • No Significant Impact of Conbercept on Serum Metabolome: Interestingly, the study found no significant differences in serum metabolic profiles before and after conbercept treatment. This suggests that the observed metabolic differences are likely pre-existing factors influencing response, rather than being a direct consequence of the drug's action on the overall serum metabolome.

Key Results

  • A total of 248 metabolites were detected in the serum samples.
  • 85 differential metabolites were identified between responders and non-responders.
  • The metabolism of LPC (p = 7.16 x 10^-19) and diacylglycerophosphocholine (p = 6.96 x 10^-17) showed the most significant differences.
  • LPC 18:0 achieved the highest AUC of 0.896 for discriminating responders in the discovery group.
  • The predictive accuracy of LPC 18:0 was 72.4% in the validation group.
  • A single nucleotide polymorphism (SNP) in the von Willebrand Factor (vWF) gene was found to be highly relevant to the level of LPC 18:0.

Limitations and Future Work

The authors acknowledge several limitations:

  • Sample Size: While a validation group was used, the overall sample size could still influence the repeatability of the results.
  • Treatment Specificity: The study focused only on conbercept. Further research is needed to determine if these findings extend to other anti-VEGF drugs.
  • Response Definition: The definition of treatment response was based on a single time point (1 month post-injection). More longitudinal studies are recommended to understand response over time and across different treatment regimens (e.g., "3 + PRN").

Future work should focus on confirming these findings in larger, diverse populations and with other anti-VEGF agents. Further investigation into the precise mechanisms by which LPC and vWF influence treatment response is also warranted.

Summary updated

Abstract

<b>Background:</b> Neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) are major causes of blindness in aged people. 30% of the patients show unsatisfactory response to anti-vascular endothelial growth factor (anti-VEGF) drugs. This study aims to investigate the relationship between serum metabolome and treatment response to anti-VEGF therapy. <b>Methods:</b> A prospective longitudinal study was conducted between March 2017 and April 2019 in 13 clinical sites in China. The discovery group were enrolled from Shanghai General Hospital. The validation group consisted of patients from the other 12 sites. Participants received at least one intravitreal injection of 0.5 mg anti-VEGF drug, conbercept, and were divided into two groups - responders and non-responders. Serum samples of both groups were processed for UHPLC-MS/MS analysis. We constructed principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA) models to investigate the metabolic differences between two groups using SIMCA-P. Area under curve (AUC) was calculated to screen the biomarkers to predict treatment response. Metabolites sub-classes and enriched pathways were obtained using MetaboAnalyst5.0. <b>Results:</b> 219 eyes from 219 patients (nAMD = 126; PCV = 93) were enrolled. A total of 248 metabolites were detected. PCA and PLS-DA models of the discovery group demonstrated that the metabolic profiles of responders and non-responders clearly differed. Eighty-five differential metabolites were identified, including sub-classes of diacylglycerophosphocholines, lysophosphatidylcholine (LPC), fatty acids, phosphocholine, etc. Responders and non-responders differed most significantly in metabolism of LPC (<i>p</i> = 7.16 × 10^-19) and diacylglycerophosphocholine (<i>p</i> = 6.96 × 10^-17). LPC 18:0 exhibited the highest AUC, which is 0.896 with 95% confidence internal between 0.833 and 0.949, to discriminate responders. The predictive accuracy of LPC 18:0 was 72.4% in the validation group. <b>Conclusions:</b> This study suggests that differential metabolites may be useful for guiding treatment options for nAMD and PCV. Metabolism of LPC and diacylglycerophosphocholine were found to affect response to conbercept treatment. LPC 18:0 was a potential biomarker to discriminate responders from non-responders.
BibTeX
@inproceedings{shen2022metabolomics,
  author = {Yinchen Shen and Hanying Wang and Xiaoyin Xu and Chong Chen and Shaopin Zhu and Lu Cheng and Junwei Fang and Kun Liu and Xun Xu},
  title = {{Metabolomics study of treatment response to conbercept of patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.991879},
}
Figure